| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TGX221 | CTRPv2 | pan-cancer | AAC | -0.032 | 0.4 |
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | -0.026 | 0.4 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | MK 1775 | CTRPv2 | pan-cancer | AAC | 0.029 | 0.4 |
| mRNA | semagacestat | CTRPv2 | pan-cancer | AAC | -0.032 | 0.4 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.033 | 0.4 |
| mRNA | CR-1-31B | CTRPv2 | pan-cancer | AAC | 0.028 | 0.4 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | BRD-K26531177 | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | KU-60019 | CTRPv2 | pan-cancer | AAC | 0.029 | 0.4 |